The rare association of dermatomyositis secondary to Chikungunya in chronic phase




Chikingunya Fever; Arthralgia; Autoimmune Diseases; Muscle weakness.


Chikungunya is an infectious tropical disease caused by Chikungunya virus (CHIKV), an RNA virus that belongs to the alphavirus genus of the family Togaviridae. It is a mosquito-borne viral disease transmitted by bites of Aedes aegypti and Aedes albopictus, most commonly. The disease evolves in three stages: acute, subacute and chronic. The chronic phase begins after 3 months of initial symptoms. Myalgia is one of the most prevalent symptoms in the disease and may be intense. In the literature, some Myopathy cases secondary to Chikungunya in acute phase were described, but few have been reported in the chronic disease. We present a case of a female patient, who developed progressive muscular weakness due to dermatomyositis in 2016 after 2 years of infection with CHIKV.


Agarwal, A., Vibha, D., Srivastava, A. K., Shukla, G., & Prasad, K. (2017). Guillain-Barre syndrome complicating chikungunya virus infection. Journal of neurovirology, 23(3), 504–507.

Alouani, I., Fihmi, N., Zizi, N., & Dikhaye, S. (2017). Dermatomyositis revealing both a metastatic linitis plastica and hepatitis C virus infection. Indian journal of dermatology, venereology and leprology, 83(5), 606–609.

Bandyopadhyay, D., & Ghosh, S. K. (2008). Mucocutaneous features of Chikungunya fever: a study from an outbreak in West Bengal, India. International journal of dermatology, 47(11), 1148–1152.

Blijham, P. J., Hengstman, G. J., Hama-Amin, A. D., van Engelen, B. G., & Zwarts, M. J. (2006). Needle electromyographic findings in 98 patients with myositis. European neurology, 55(4), 183–188.

Brasil. (2015). Monitoramento dos casos de dengue e febre de chikungunya até a Semana Epidemiológica 15. Ministério da Saúde.

Callen JP, Wortmann RL. Dermatomyositis. Clin Dermatol. 2006 Sep-Oct;24(5):363-73. doi: 10.1016/j.clindermatol.2006.07.001. PMID: 16966018.

Cardona-Ospina, J. A., Rodriguez-Morales, A. J., & Villamil-Gómez, W. E. (2015). The burden of Chikungunya in one coastal department of Colombia (Sucre): Estimates of the disability adjusted life years (DALY) lost in the 2014 epidemic. Journal of infection and public health, 8(6), 644–646.

Cardona-Ospina, J. A., Villamil-Gómez, W. E., Jimenez-Canizales, C. E., Castañeda-Hernández, D. M., & Rodríguez-Morales, A. J. (2015). Estimating the burden of disease and the economic cost attributable to chikungunya, Colombia, 2014. Transactions of the Royal Society of Tropical Medicine and Hygiene, 109(12), 793–802.

Cunha, Rivaldo V da, & Trinta, Karen S. (2017). Chikungunya virus: clinical aspects and treatment - A Review. Memórias do Instituto Oswaldo Cruz, 112(8), 523-531.

DeWane, M. E., Waldman, R., & Lu, J. (2020). Dermatomyositis: Clinical features and pathogenesis. Journal of the American Academy of Dermatology, 82(2), 267–281.

Gan, L., & Miller, F. W. (2011). State of the art: what we know about infectious agents and myositis. Current opinion in rheumatology, 23(6), 585–594.

Guilherme, L., Dulphy, N., Douay, C., Coelho, V., Cunha-Neto, E., Oshiro, S. E., Assis, R. V., Tanaka, A. C., Pomerantzeff, P. M., Charron, D., Toubert, A., & Kalil, J. (2000). Molecular evidence for antigen-driven immune responses in cardiac lesions of rheumatic heart disease patients. International immunology, 12(7), 1063–1074.

Madan, V., Chinoy, H., Griffiths, C. E., & Cooper, R. G. (2009). Defining cancer risk in dermatomyositis. Part I. Clinical and experimental dermatology, 34(4), 451–455.

Marc Hochberg , M.R. (2018). Rheumatology. (7 ed.). Elsevier.

Mathew, A. J., Goyal, V., George, E., Thekkemuriyil, D. V., Jayakumar, B., Chopra, A., & Trivandrum COPCORD Study Group (2011). Rheumatic-musculoskeletal pain and disorders in a naïve group of individuals 15 months following a Chikungunya viral epidemic in south India: a population based observational study. International journal of clinical practice, 65(12), 1306–1312.

Miller, F. W., Pollard, K. M., Parks, C. G., Germolec, D. R., Leung, P. S., Selmi, C., Humble, M. C., & Rose, N. R. (2012). Criteria for environmentally associated autoimmune diseases. Journal of autoimmunity, 39(4), 253–258.

Morrison, T. E., Oko, L., Montgomery, S. A., Whitmore, A. C., Lotstein, A. R., Gunn, B. M., Elmore, S. A., & Heise, M. T. (2011). A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence. The American journal of pathology, 178(1), 32–40.

Rahim, A. A., Thekkekara, R. J., Bina, T., & Paul, B. J. (2016). Disability with Persistent Pain Following an Epidemic of Chikungunya in Rural South India. The Journal of rheumatology, 43(2), 440–444.

Ren, Z., Laumann, A. E., & Silverberg, J. I. (2019). Association of dermatomyositis with systemic and opportunistic infections in the United States. Archives of dermatological research, 311(5), 377–387.

Rodríguez-Morales, A. J., Cardona-Ospina, J. A., Fernanda Urbano-Garzón, S., & Sebastian Hurtado-Zapata, J. (2016). Prevalence of Post-Chikungunya Infection Chronic Inflammatory Arthritis: A Systematic Review and Meta-Analysis. Arthritis care & research, 68(12), 1849–1858.

Seidler, A. M., & Gottlieb, A. B. (2008). Dermatomyositis induced by drug therapy: a review of case reports. Journal of the American Academy of Dermatology, 59(5), 872–880.

YIN, R. K. (2015). Estudo de caso: planejamento e métodos (5a ed.). (C. M. Herrera, Trad.). Porto Alegre: Bookman. (Obra original publicada em 1984).

Zandman-Goddard, G., & Shoenfeld, Y. (2005). Infections and SLE. Autoimmunity, 38(7), 473–485.

Zheng, Q., Zhu, K., Gao, C. N., Xu, Y. P., & Lu, M. P. (2019). Prevalence of Epstein-Barr virus infection and characteristics of lymphocyte subsets in newly onset juvenile dermatomyositis. World journal of pediatrics: WJP, 10.1007/s12519-019-00314-7. Advance online publication.



How to Cite

ARRIAGA, N. C.; SALLES, L. C.; SILVA, F. T. M.; COSTA, F. A. M. da; RODRIGUES, C. L.; AUGUSTO, K. L. The rare association of dermatomyositis secondary to Chikungunya in chronic phase . Research, Society and Development, [S. l.], v. 10, n. 5, p. e17010514865, 2021. DOI: 10.33448/rsd-v10i5.14865. Disponível em: Acesso em: 2 dec. 2023.



Health Sciences